• AstraZeneca’s Enhertu won FDA clearance for neoadjuvant use in adults with HER2-positive Stage II-III early breast cancer, expanding the drug into the curative-intent setting.
• The label also now covers adjuvant use for patients with residual invasive disease following trastuzumab-based therapy and taxane chemotherapy.
• A milestone payment of USD 155 million is due from AstraZeneca to partner Daiichi Sankyo following the two US approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202605152152BIZWIRE_USPR_____20260515_BW255054) on May 16, 2026, and is solely responsible for the information contained therein.